

[Request Information](#)

[Permalink](#)

CLASS 2 CRISPR/CAS COMPOSITIONS AND METHODS OF USE

Tech ID: 28923 / UC Case 2018-048-0

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	11,970,719	04/30/2024	2018-048

BRIEF DESCRIPTION

The CRISPR-Cas system is now understood to confer bacteria and archaea with acquired immunity against phage and viruses. CRISPR-Cas systems consist of Cas proteins, which are involved in acquisition, targeting and cleavage of foreign DNA or RNA, and a CRISPR array, which includes direct repeats flanking short spacer sequences that guide Cas proteins to their targets. Class 2 CRISPR-Cas systems are streamlined versions in which a single Cas protein bound to RNA is responsible for binding to and cleavage of a targeted sequence. The programmable nature of these minimal systems has facilitated their use as a versatile technology that is revolutionizing the field of genome manipulation, so there is a need in the art for additional Class 2 CRISPR/Cas systems (e.g., Cas protein plus guide RNA combinations).

Researchers have shown that Class 2 CRISPR Cas protein and their variants can be used in a complex for specific binding and cleavage of DNA. The Class 2 CRISPR Cas complex utilizes a novel RNA and a guide RNA to perform double stranded cleavage of DNA and the complex is expected to have a wide variety of applications in genome editing and nucleic acid manipulation.

SUGGESTED USES

- » Genome editing
- » Genetic engineering
- » Gene therapy
- » Research tools (e.g., high-throughput screening of gene functions in cell lines and *in vivo*)
- » Creation of transgenic animal models
- » Genomic imaging

ADVANTAGES

- » Adds additional versatility
- » Variant PAM

CONTACT

Terri Sale
terri.sale@berkeley.edu
tel: 510-643-4219.



INVENTORS

» Doudna, Jennifer A.

OTHER INFORMATION

KEYWORDS

CRISPR, gene editing, genome, gene therapy, cell biology, Class 2

CATEGORIZED AS

- » **Biotechnology**
- » **Genomics**
- » **Medical**
- » **Gene Therapy**
- » **Research Tools**
- » **Therapeutics**
- » **Research Tools**
- » **Nucleic Acids/DNA/RNA**
- » **Veterinary**
- » **Other**
- » **Therapeutics**

RELATED CASES

2018-048-0

- COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR TREATING RNA VIRUS INFECTIONS
- Genome Editing via LNP-Based Delivery of Efficient and Stable CRISPR-Cas Editors
- Tissue-Specific Genome Engineering Using CRISPR-Cas9
- Type III CRISPR-Cas System for Robust RNA Knockdown and Imaging in Eukaryotes
- Cas9 Variants With Altered DNA Cleaving Activity
- Cas12-mediated DNA Detection Reporter Molecules
- Improved guide RNA and Protein Design for CasX-based Gene Editing Platform
- Cas13a/C2c2 - A Dual Function Programmable RNA Endoribonuclease
- Miniature Type VI CRISPR-Cas Systems and Methods of Use
- RNA-directed Cleavage and Modification of DNA using CasY (CRISPR-CasY)
- CasX Nickase Designs, Tans Cleavage Designs & Structure
- In Vivo Gene Editing Of Tau Locus Via Liponanoparticle Delivery
- Methods and Compositions for Modifying a single stranded Target Nucleic Acid
- A Dual-RNA Guided CasZ Gene Editing Technology
- A Protein Inhibitor Of Cas9
- RNA-directed Cleavage and Modification of DNA using CasX (CRISPR-CasX)
- Compositions and Methods for Genome Editing
- IS110 and IS1111 Family RNA-Guided Transposons
- Methods to Interfere with Prokaryotic and Phage Translation and Noncoding RNA
- Variant Cas12a Protein Compositions and Methods of Use
- In Vitro and In Vivo Genome Editing by LNP Delivery of CRISPR Ribonucleoprotein
- CRISPR CASY COMPOSITIONS AND METHODS OF USE
- Single Conjugative Vector for Genome Editing by RNA-guided Transposition
- Improved Cas12a Proteins for Accurate and Efficient Genome Editing
- CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
- Methods Of Use Of Cas12L/CasLambda In Plants
- Type V CRISPR/CAS Effector Proteins for Cleaving ssDNA and Detecting Target DNA
- THERMOSTABLE RNA-GUIDED ENDONUCLEASES AND METHODS OF USE THEREOF (GeoCas9)
- Variant TnpB and wRNA Proteins
- Efficient Site-Specific Integration Of New Genetic Information Into Human Cells
- Compositions and Methods of Use for Variant Csy4 Endoribonucleases
- Immune Cell-Mediated Intercellular Delivery Of Biomolecules
- Methods and Compositions for Controlling Gene Expression by RNA Processing



University of California, Berkeley Office of Technology Licensing

2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704

Tel: 510.643.7201 | Fax: 510.642.4566

<https://ipira.berkeley.edu/> | otl-feedback@lists.berkeley.edu

© 2017 - 2024, The Regents of the University of California

[Terms of use](#) | [Privacy Notice](#)